PXL065(氘稳定化(R)-吡格列酮)治疗NASH患者:一项II期随机安慰剂对照试验(DESTINY-1)
DESTINY-1是一项II期随机安慰剂对照试验,评估PXL065(氘稳定化(R)-吡格列酮)在NASH患者中的疗效与安全性。117例患者随机接受PXL065 7.5、15、22.5 mg或安慰剂治疗36周,所有PXL065组均达到主要终点(肝脂肪含量相对降低21%–25%),组织学显示纤维化改善趋势,代谢指标改善,总体安全耐受。
要点
- 所有PXL065组肝脂肪含量相对降低21%–25%(p=0.008–0.02 vs 安慰剂),22.5 mg组40%患者降低≥30%。
- 组织学(n=92)纤维化改善≥1期:7.5 mg组40%、15 mg组50%(p=0.06)、22.5 mg组35% vs 安慰剂17%。
- PXL065安全耐受,体重和外周水肿无剂量依赖性信号,药代动力学显示R-Pio暴露高于S-Pio。
核心结论
- PXL065在NASH中保留了与吡格列酮相似的疗效特征,同时降低了PPARγ驱动副作用的风险。
- 作者认为需要一项关键性临床试验来确认本文报告的组织学获益。
研究设计与样本
- II期随机、安慰剂对照试验(DESTINY-1),患者按1:1:1:1随机接受PXL065 7.5、15、22.5 mg每日一次或安慰剂治疗36周。
- 纳入标准:肝脂肪含量≥8%、NAFLD活动度评分(NAS)≥4、纤维化分期F1-F3。
- 共评估117例患者;组织学分析纳入92例。
- 主要终点为MRI质子密度脂肪分数测定的肝脂肪含量相对百分比变化;同时评估肝组织学、无创检测、安全耐受性和药代动力学。
主要发现
- 所有PXL065组均达到主要终点:肝脂肪含量相对降低21%–25%(p=0.008–0.02 vs 安慰剂);22.5 mg组40%患者实现肝脂肪含量降低≥30%。
- 无创检测有利趋势:22.5 mg组PIIINP降低(p=0.02)、NAFLD纤维化评分降低(p=0.04)。
- 组织学(n=92)纤维化改善≥1期:7.5 mg组40%、15 mg组50%(p=0.06)、22.5 mg组35% vs 安慰剂17%;PXL065治疗组高达50%患者实现NAS改善≥2分且纤维化未恶化 vs 安慰剂30%。
- 代谢改善:HbA1c降低0.41%(p=0.003)、胰岛素敏感性改善(HOMA-IR p=0.04;Adipo-IR p=0.002);22.5 mg组脂联素增加114%(p<0.0001)vs 安慰剂。
- 体重和外周水肿无剂量依赖性效应;PXL065总体安全耐受;药代动力学确认剂量比例性暴露,稳态R-Pio暴露高于S-Pio。
关键数值与推荐
- 主要终点:肝脂肪含量相对降低21%–25%(PXL065各组 vs 安慰剂,p=0.008–0.02)。
- 22.5 mg组40%患者肝脂肪含量降低≥30%。
- 组织学纤维化改善≥1期:7.5 mg组40%、15 mg组50%(p=0.06)、22.5 mg组35% vs 安慰剂17%。
- NAS改善≥2分且纤维化未恶化:PXL065治疗组高达50% vs 安慰剂30%。
- 22.5 mg组HbA1c降低0.41%(p=0.003)、脂联素增加114%(p<0.0001)vs 安慰剂。
临床怎么用
- 原文结论未据此给出临床推荐。
- 作者认为PXL065需要进一步开展关键性临床试验,以确认本文报告的组织学获益。
- 作者指出这些结果提示PXL065未来可能成为一种用于NASH的独特口服治疗选择。
局限性
- 原文结论指出需要一项关键性临床试验来确认本文报告的组织学获益。
- 原文指出这些结果提示PXL065需要进一步的临床测试(关键性NASH试验)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pioglitazone (Pio) is efficacious in NASH, but its utility is limited by PPARγ-driven side effects. Pio is a mixture of two enantiomers (R, S). PXL065, deuterium-stabilized R-Pio, lacks PPARγ activity but retains non-genomic activity. We tested the hypothesis that PXL065 would have similar efficacy but a better safety profile than Pio in patients with NASH. METHODS: Patients (≥8% liver fat, NAFLD activity score [NAS] ≥4, F1-F3) received daily doses of PXL065 (7.5, 15, 22.5 mg) or placebo 1:1:1:1 for 36 weeks. The primary endpoint was relative % change in liver fat content (LFC) on MRI-proton density fat fraction; liver histology, non-invasive tests, safety-tolerability, and pharmacokinetics were also assessed. RESULTS: One hundred and seventeen patients were evaluated. All PXL065 groups met the primary endpoint (-21 to -25% LFC, p = 0.008-0.02 vs. placebo); 40% (22.5 mg) achieved a ≥30% LFC reduction. Favorable trends in non-invasive tests including reductions in PIIINP (p = 0.02, 22.5 mg) and NAFLD fibrosis score (p = 0.04, 22.5 mg) were observed. On histology (n = 92), a ≥1 stage fibrosis improvement occurred in 40% (7.5 mg), 50% (15 mg, p = 0.06), and 35% (22.5 mg) vs. 17% for placebo; up to 50% of PXL065-treated patients achieved a ≥2 point NAS improvement without fibrosis worsening vs. 30% with placebo. Metabolic improvements included: HbA1c (-0.41% p = 0.003) and insulin sensitivity (HOMA-IR, p = 0.04; Adipo-IR, p = 0.002). Adiponectin increased (+114%, 22.5 mg, p <0.0001) vs. placebo. There was no dose-dependent effect on body weight or PXL065-related peripheral oedema signal. Overall, PXL065 was safe and well tolerated. Pharmacokinetics confirmed dose-proportional and higher steady state R- vs. S-Pio exposure. IMPACT AND IMPLICATIONS: Pioglitazone (Pio) is an approved diabetes medicine with proven efficacy in non-alcoholic steatohepatitis (NASH); PXL065 is a novel related oral agent which has been shown to retain Pio's efficacy in preclinical NASH models, with reduced potential for PPARγ-driven side effects. Results of this phase II study are important as PXL065 improved several key NASH disease features with a favorable safety profile - these findings can be applied by researchers seeking to understand pathophysiology and to develop new therapies. These results also indicate that PXL065 warrants further clinical testing in a pivotal NASH trial. Other implications include the potential future availability of a distinct oral therapy for NASH that may be relevant for patients, providers and caregivers seeking to prevent the progression and complications of this disease. CONCLUSIONS: PXL065 is a novel molecule which retains an efficacy profile in NASH similar to Pio with reduced potential for PPARγ-driven side effects. A pivotal clinical trial is warranted to confirm the histological benefits reported herein. IMPACT AND IMPLICATIONS: Pioglitazone (Pio) is an approved diabetes medicine with proven efficacy in non-alcoholic steatohepatitis (NASH); PXL065 is a novel related oral agent which has been shown to retain Pio's efficacy in preclinical NASH models, with reduced potential for PPARγ-driven side effects. Results of this phase II study are important as PXL065 improved several key NASH disease features with a favorable safety profile - these findings can be applied by researchers seeking to understand pathophysiology and to develop new therapies. These results also indicate that PXL065 warrants further clinical testing in a pivotal NASH trial. Other implications include the potential future availability of a distinct oral therapy for NASH that may be relevant for patients, providers and caregivers seeking to prevent the progression and complications of this disease.
引用
- Harrison SA, Thang C, Bolze S, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol. 2023. PMID: 36804402. doi:10.1016/j.jhep.2023.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。